GSK 2302025A

Drug Profile

GSK 2302025A

Alternative Names: GSK2302025A; PRAME Antigen Specific Cancer Immunotherapeutic - Melanoma; PRAME-ASCI-melanoma

Latest Information Update: 25 Sep 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlaxoSmithKline
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Malignant melanoma

Most Recent Events

  • 08 Feb 2013 GlaxoSmithKline completes enrolment in its phase I/II trial for Mestatatic melanoma (first-line therapy) in Czech Republic, France, Germany, Italy, Poland and Russia (NCT01149343)
  • 03 Dec 2010 Phase-I/II clinical trials in Malignant melanoma (first-line therapy, metastatic disease) in Russia (IM)
  • 24 Nov 2010 Phase-I/II clinical trials in Malignant melanoma (first-line therapy, metastatic disease) in Poland (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top